HUE051711T2 - Influenzavakcina antigénjeinek koncentrálása liofilizálás nélkül - Google Patents

Influenzavakcina antigénjeinek koncentrálása liofilizálás nélkül

Info

Publication number
HUE051711T2
HUE051711T2 HUE11743338A HUE11743338A HUE051711T2 HU E051711 T2 HUE051711 T2 HU E051711T2 HU E11743338 A HUE11743338 A HU E11743338A HU E11743338 A HUE11743338 A HU E11743338A HU E051711 T2 HUE051711 T2 HU E051711T2
Authority
HU
Hungary
Prior art keywords
lyophilization
concentration
influenza vaccine
vaccine antigens
antigens
Prior art date
Application number
HUE11743338A
Other languages
English (en)
Inventor
Sushma Kommareddy
Amanda Scampini
Barbara Baudner
Derek O'hagan
Manmohan Singh
Original Assignee
Seqirus Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seqirus Uk Ltd filed Critical Seqirus Uk Ltd
Publication of HUE051711T2 publication Critical patent/HUE051711T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16311—Influenzavirus C, i.e. influenza C virus
    • C12N2760/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16311—Influenzavirus C, i.e. influenza C virus
    • C12N2760/16351—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Water Supply & Treatment (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Surgical Instruments (AREA)
HUE11743338A 2010-06-01 2011-06-01 Influenzavakcina antigénjeinek koncentrálása liofilizálás nélkül HUE051711T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39671910P 2010-06-01 2010-06-01
US201161465405P 2011-03-18 2011-03-18

Publications (1)

Publication Number Publication Date
HUE051711T2 true HUE051711T2 (hu) 2021-03-29

Family

ID=45067143

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE11743338A HUE051711T2 (hu) 2010-06-01 2011-06-01 Influenzavakcina antigénjeinek koncentrálása liofilizálás nélkül

Country Status (15)

Country Link
US (1) US20130224245A1 (hu)
EP (2) EP2575872B1 (hu)
JP (1) JP5959508B2 (hu)
KR (5) KR20130109004A (hu)
CN (1) CN103096921A (hu)
AU (1) AU2011262309B2 (hu)
BR (1) BR112012030619A2 (hu)
CA (1) CA2801149A1 (hu)
DK (1) DK2575872T3 (hu)
EA (1) EA201291437A1 (hu)
ES (1) ES2825712T3 (hu)
HU (1) HUE051711T2 (hu)
PL (1) PL2575872T3 (hu)
PT (1) PT2575872T (hu)
WO (1) WO2011151723A2 (hu)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2531577T3 (es) * 2010-08-20 2015-03-17 Novartis Ag Conjuntos de agujas para la administración de vacuna soluble contra la gripe
US9827190B2 (en) 2013-02-01 2017-11-28 Glaxosmithkline Biologicals Sa Intradermal delivery of immunological compositions comprising toll-like receptor 7 agonists
WO2017005880A1 (en) * 2015-07-07 2017-01-12 Seqirus UK Limited Influenza potency assays
US11628208B2 (en) * 2015-10-05 2023-04-18 The Corporation Of Mercer University System and method for microneedle delivery of microencapsulated vaccine and bioactive proteins
WO2017062463A1 (en) * 2015-10-05 2017-04-13 The Corporation Of Mercer University Nanospheres encapsulating bioactive material and method for formulation of nanospheres
MX2018012477A (es) * 2016-04-14 2019-03-07 Merial Inc Composiciones de multiples dosis que contienen un conservador de poliamida antimicrobiana u octenidina.
US11311496B2 (en) 2016-11-21 2022-04-26 Eirion Therapeutics, Inc. Transdermal delivery of large agents
US20220031595A1 (en) * 2018-12-03 2022-02-03 Eirion Therapeutics, Inc. Improved delivery of large agents

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US4988815A (en) 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
WO1992015582A1 (en) 1991-03-01 1992-09-17 Minnesota Mining And Manufacturing Company 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO[4,5-c]QUINOLIN-4-AMINES
US5762939A (en) 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
BR9506484A (pt) 1994-01-11 1997-10-07 Vlaams Interuniv Inst Biotech Neuraminidase recombinate seu vetor processo para sua manufatura e uso como vacina contra influenza
DE19612967A1 (de) 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
AU7126998A (en) 1997-04-16 1998-11-11 Connaught Laboratories Inc. Anti-influenza compositions supplemented with neuraminidase
US20030130212A1 (en) 1999-01-14 2003-07-10 Rossignol Daniel P. Administration of an anti-endotoxin drug by intravenous infusion
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
EP1878424A3 (en) 1999-09-24 2008-04-09 GlaxoSmithKline Biologicals S.A. Novel vaccine
AU3604201A (en) 2000-03-03 2001-09-12 Chemo Sero Therapeut Res Inst Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell
FR2808803B1 (fr) 2000-05-11 2004-12-10 Agronomique Inst Nat Rech Cellules es modifiees et gene specifique de cellules es
GB0017999D0 (en) * 2000-07-21 2000-09-13 Smithkline Beecham Biolog Novel device
GB0024089D0 (en) 2000-10-02 2000-11-15 Smithkline Beecham Biolog Novel compounds
US7803392B2 (en) 2000-12-27 2010-09-28 University Of Kentucky Research Foundation pH-Sensitive mucoadhesive film-forming gels and wax-film composites suitable for topical and mucosal delivery of molecules
WO2002074336A2 (en) 2001-02-23 2002-09-26 Glaxosmithkline Biologicals S.A. Influenza vaccine formulations for intradermal delivery
US20040096463A1 (en) 2001-02-23 2004-05-20 Nathalie Garcon Novel vaccine
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
WO2003004341A1 (fr) 2001-06-30 2003-01-16 Haiyue Zhang Bicyclette multifonction permettant de faire de l'exercice et de la gymnastique
DE10144903A1 (de) 2001-09-12 2003-03-27 Chiron Behring Gmbh & Co Vermehrung von Viren in Zellkultur
DE10144906B4 (de) 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
FR2832423B1 (fr) 2001-11-22 2004-10-08 Vivalis Systeme d'expression de proteines exogenes dans un systeme aviaire
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
US6945952B2 (en) 2002-06-25 2005-09-20 Theraject, Inc. Solid solution perforator for drug delivery and other applications
AR040819A1 (es) * 2002-08-08 2005-04-20 Alza Corp Dispositivo de administracion transdermica de vacuna que tiene microproyecciones revestidas
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
US20050220854A1 (en) * 2004-04-01 2005-10-06 Yuh-Fun Maa Apparatus and method for transdermal delivery of influenza vaccine
WO2005113756A1 (en) 2004-05-14 2005-12-01 Glaxosmithkline Biologicals S.A. Method
CA2566759A1 (en) * 2004-05-19 2005-11-24 Alza Corporation Method and formulation for transdermal delivery of immunologically active agents
CN101094915A (zh) 2004-05-20 2007-12-26 益得生物医学公司 生产流感疫苗的方法
EP2179744B1 (en) 2004-09-09 2010-12-01 Novartis Vaccines and Diagnostics GmbH Decreasing potential latrogenic risks associated with influenza vaccines
JP5414178B2 (ja) 2004-12-23 2014-02-12 メディミューン，エルエルシー ウイルス増殖用の非腫瘍形成性ｍｄｃｋ細胞株
CA2602944C (en) * 2005-04-11 2015-08-11 Crucell Holland B.V. Virus purification using ultrafiltration
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
EP1940459B1 (en) 2005-09-06 2014-04-09 Theraject, Inc. Solid solution perforator containing drug particle and/or drug-adsorbed particles
CN101365480B (zh) 2005-11-01 2014-11-05 诺华疫苗和诊断有限两合公司 经由β-丙内酯处理的残留细胞DNA水平降低的细胞衍生病毒疫苗
EP1948139A4 (en) 2005-11-18 2012-04-04 3M Innovative Properties Co COATING COMPOSITIONS, COATINGS DERIVED THEREFROM, AND MICRO-NETWORKS COMPRISING SUCH COATINGS
CA2627542A1 (en) 2005-11-18 2007-05-24 3M Innovative Properties Company Microneedle arrays and methods of preparing same
WO2007124393A2 (en) 2006-04-20 2007-11-01 3M Innovative Properties Company Molded articles comprising microneedle arrays
WO2008068631A2 (en) * 2006-12-06 2008-06-12 Novartis Ag Vaccines including antigen from four strains of influenza virus
US9452209B2 (en) * 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
PL2175881T3 (pl) * 2007-06-14 2012-12-31 Crucell Switzerland Ag Śródskórna szczepionka przeciwko grypie
NZ582595A (en) 2007-06-27 2012-07-27 Novartis Ag Low-additive influenza vaccines
WO2010002418A2 (en) 2008-07-01 2010-01-07 The Johns Hopkins University Quick-dissolving oral thin film for targeted delivery of therapeutic agents
CA2734381A1 (en) * 2008-09-12 2010-03-18 Critical Pharmaceuticals Limited Improvements in the absorption of therapeutic agents across mucosal membranes or the skin
KR20110074563A (ko) * 2008-09-24 2011-06-30 메디뮨 엘엘씨 바이러스의 정제 방법

Also Published As

Publication number Publication date
KR102471356B1 (ko) 2022-11-28
KR20210154996A (ko) 2021-12-21
KR102113512B1 (ko) 2020-05-22
JP5959508B2 (ja) 2016-08-02
AU2011262309B2 (en) 2015-08-13
KR20180096829A (ko) 2018-08-29
EP3827843A1 (en) 2021-06-02
PL2575872T3 (pl) 2021-02-22
EP2575872A2 (en) 2013-04-10
KR20220163497A (ko) 2022-12-09
CN103096921A (zh) 2013-05-08
KR20200057097A (ko) 2020-05-25
CA2801149A1 (en) 2011-12-08
ES2825712T3 (es) 2021-05-17
EA201291437A1 (ru) 2013-05-30
WO2011151723A2 (en) 2011-12-08
KR20130109004A (ko) 2013-10-07
US20130224245A1 (en) 2013-08-29
DK2575872T3 (da) 2020-10-19
EP2575872B1 (en) 2020-08-19
BR112012030619A2 (pt) 2019-09-24
PT2575872T (pt) 2020-11-19
JP2013534912A (ja) 2013-09-09
WO2011151723A3 (en) 2012-06-07
AU2011262309A1 (en) 2012-12-20

Similar Documents

Publication Publication Date Title
IL262123A (en) Influenza virus vaccines and their uses
IL261204A (en) Influenza virus vaccines and their use
PL2575873T3 (pl) Zatężanie i liofilizacja antygenów szczepionkowych grypy
HK1245128A1 (zh) 針對人腸道病毒的抗原及疫苗
HK1199211A1 (en) Influenza virus vaccines and uses thereof
EP2552479A4 (en) INFLUENZA VIRUS VACCINES AND USES THEREOF
DK3170508T3 (da) Vaccineformuleringer
PT2575872T (pt) Concentração de antigénios da vacina da gripe sem liofilização
IL229307A0 (en) Inactivated dengue virus vaccine
HK1203523A1 (en) Computationally optimized broadly reactive antigens for human and avian h5n1 influenza h5n1
EP2726097A4 (en) HERPES VIRUS VACCINE AND METHOD OF USE
IL224022B (en) Thermally stable influenza vaccine
ZA201300395B (en) Influenza vaccine
SMT201700046B (it) Micobatterio ricombinante come vaccino
PL2755680T3 (pl) Preparaty szczepionkowe w postaci cząstek
EP2852396A4 (en) INFLUENZA VACCINE CONSTRUCTS
EP2897639A4 (en) IMPROVED VACCINE COMPOSITIONS AND METHODS OF USE
EP2694102A4 (en) PROCESS FOR IMPROVED VACCINE IMMUNOGENICITY
EP2522360A4 (en) VACCINE FOR TAUTOPATHY TREATMENT
CL2015001618A1 (es) Adyuvante de vacunación, preparación y vacunas que lo contienen
BR112013027457A2 (pt) preparação de vacina, e, métodos de fabricar uma preparação de vacina, e de vacinar um mamífero
HK1201283A1 (en) Influenza c virus and vaccine
EP2615104A4 (en) LIPOSOMAL VACCINE AGAINST HEPATITIS C VIRUS
HK1213949A1 (zh) 活疫苗製備
GB201003332D0 (en) Efficient preparation of combination vaccines